Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 102 entries
Sorted by: Best Match Show Resources per page
Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs.

Meta gene

Willis S, De P, Dey N, Long B, Young B, Sparano JA, Wang V, Davidson NE, Leyland-Jones BR.
PMID: 26005638
Meta Gene. 2015 May 15;4:129-41. doi: 10.1016/j.mgene.2015.04.002. eCollection 2015 Jun.

PURPOSE: Triple negative (TN) breast cancers which lack expression of the estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors convey a poor prognosis due in part to a lack of targeted therapies.METHODS: To identify viable...

Cite
Willis S, De P, Dey N, et al. Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene. 2015;4:129-41doi: 10.1016/j.mgene.2015.04.002.
Willis, S., De, P., Dey, N., Long, B., Young, B., Sparano, J. A., Wang, V., Davidson, N. E., & Leyland-Jones, B. R. (2015). Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta gene, 4129-41. https://doi.org/10.1016/j.mgene.2015.04.002
Willis, Scooter, et al. "Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs." Meta gene vol. 4 (2015): 129-41. doi: https://doi.org/10.1016/j.mgene.2015.04.002
Willis S, De P, Dey N, Long B, Young B, Sparano JA, Wang V, Davidson NE, Leyland-Jones BR. Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene. 2015 May 15;4:129-41. doi: 10.1016/j.mgene.2015.04.002. eCollection 2015 Jun. PMID: 26005638; PMCID: PMC4436509.
Copy Download .nbib Format: NLM
Reply to C. Shah et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE.
PMID: 27001578
J Clin Oncol. 2016 May 20;34(15):1824-5. doi: 10.1200/JCO.2016.66.4714. Epub 2016 Mar 21.

No abstract available.

Cite
Solin LJ, Gray R, Hughes LL, et al. Reply to C. Shah et al. J Clin Oncol. 2016;34(15):1824-5doi: 10.1200/JCO.2016.66.4714.
Solin, L. J., Gray, R., Hughes, L. L., Wood, W. C., Lowen, M. A., Badve, S. S., Baehner, F. L., Ingle, J. N., Perez, E. A., Recht, A., Sparano, J. A., & Davidson, N. E. (2016). Reply to C. Shah et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(15), 1824-5. https://doi.org/10.1200/JCO.2016.66.4714
Solin, Lawrence J, et al. "Reply to C. Shah et al." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 34,15 (2016): 1824-5. doi: https://doi.org/10.1200/JCO.2016.66.4714
Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Reply to C. Shah et al. J Clin Oncol. 2016 May 20;34(15):1824-5. doi: 10.1200/JCO.2016.66.4714. Epub 2016 Mar 21. PMID: 27001578.
Copy Download .nbib Format: NLM
The Role of Wearable Devices in Multiple Sclerosis.

Multiple sclerosis international

Sparaco M, Lavorgna L, Conforti R, Tedeschi G, Bonavita S.
PMID: 30405913
Mult Scler Int. 2018 Oct 10;2018:7627643. doi: 10.1155/2018/7627643. eCollection 2018.

Multiple sclerosis (MS) is the most common neurological disorder in young adults. The prevalence of walking impairment in people with MS (pwMS) is estimated between 41% and 75%. To evaluate the walking capacity in pwMS, the patient reported outcomes...

Cite
Sparaco M, Lavorgna L, Conforti R, et al. The Role of Wearable Devices in Multiple Sclerosis. Mult Scler Int. 2018;2018:7627643doi: 10.1155/2018/7627643.
Sparaco, M., Lavorgna, L., Conforti, R., Tedeschi, G., & Bonavita, S. (2018). The Role of Wearable Devices in Multiple Sclerosis. Multiple sclerosis international, 20187627643. https://doi.org/10.1155/2018/7627643
Sparaco, Maddalena, et al. "The Role of Wearable Devices in Multiple Sclerosis." Multiple sclerosis international vol. 2018 (2018): 7627643. doi: https://doi.org/10.1155/2018/7627643
Sparaco M, Lavorgna L, Conforti R, Tedeschi G, Bonavita S. The Role of Wearable Devices in Multiple Sclerosis. Mult Scler Int. 2018 Oct 10;2018:7627643. doi: 10.1155/2018/7627643. eCollection 2018. PMID: 30405913; PMCID: PMC6199873.
Copy Download .nbib Format: NLM
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.

NPJ breast cancer

Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, Sparano JA, Connolly RM.
PMID: 29354686
NPJ Breast Cancer. 2018 Jan 11;4:1. doi: 10.1038/s41523-017-0053-3. eCollection 2018.

Endocrine therapies are effective in the treatment of hormone receptor (HR)-positive breast cancer, however, de novo or acquired treatment resistance is a significant clinical problem. A potential mechanism of resistance involves changes in gene expression secondary to epigenetic modifications,...

Cite
Yeruva SLH, Zhao F, Miller KD, et al. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer. 2018;4:1doi: 10.1038/s41523-017-0053-3.
Yeruva, S. L. H., Zhao, F., Miller, K. D., Tevaarwerk, A. J., Wagner, L. I., Gray, R. J., Sparano, J. A., & Connolly, R. M. (2018). E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ breast cancer, 41. https://doi.org/10.1038/s41523-017-0053-3
Yeruva, Sri Lakshmi Hyndavi, et al. "E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer." NPJ breast cancer vol. 4 (2018): 1. doi: https://doi.org/10.1038/s41523-017-0053-3
Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, Sparano JA, Connolly RM. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer. 2018 Jan 11;4:1. doi: 10.1038/s41523-017-0053-3. eCollection 2018. PMID: 29354686; PMCID: PMC5765007.
Copy Download .nbib Format: NLM
Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy.

Cancer

Garcia SF, Gray RJ, Sparano JA, Tevaarwerk AJ, Carlos RC, Yanez B, Gareen IF, Whelan TJ, Sledge GW, Cella D, Wagner LI.
PMID: 34614209
Cancer. 2021 Oct 06; doi: 10.1002/cncr.33939. Epub 2021 Oct 06.

BACKGROUND: TAILORx (Trial Assigning Individualized Options for Treatment) prospectively assessed fatigue and endocrine symptoms among women with early-stage hormone receptor-positive breast cancer and a midrange risk of recurrence who were randomized to endocrine therapy (E) or chemotherapy followed by...

Cite
Garcia SF, Gray RJ, Sparano JA, et al. Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. Cancer. 2021;doi: 10.1002/cncr.33939.
Garcia, S. F., Gray, R. J., Sparano, J. A., Tevaarwerk, A. J., Carlos, R. C., Yanez, B., Gareen, I. F., Whelan, T. J., Sledge, G. W., Cella, D., & Wagner, L. I. (2021). Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. Cancer, . https://doi.org/10.1002/cncr.33939
Garcia, Sofia F, et al. "Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.33939
Garcia SF, Gray RJ, Sparano JA, Tevaarwerk AJ, Carlos RC, Yanez B, Gareen IF, Whelan TJ, Sledge GW, Cella D, Wagner LI. Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. Cancer. 2021 Oct 06; doi: 10.1002/cncr.33939. Epub 2021 Oct 06. PMID: 34614209.
Copy Download .nbib Format: NLM
Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.

Journal of the National Cancer Institute

Kantor O, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Burstein HJ, Winer EP, Dey T, Sparano JA, Mittendorf EA.
PMID: 34010423
J Natl Cancer Inst. 2021 May 19; doi: 10.1093/jnci/djab095. Epub 2021 May 19.

BACKGROUND: The prognostic significance of patients with low-risk Recurrence Score (RS) results in the context of the American Joint Committee on Cancer (AJCC) 8th-edition pathologic prognostic staging has not been investigated. We evaluated if expanded RS criteria can be...

Cite
Kantor O, King TA, Shak S, et al. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Natl Cancer Inst. 2021;doi: 10.1093/jnci/djab095.
Kantor, O., King, T. A., Shak, S., Russell, C. A., Giuliano, A. E., Hortobagyi, G. N., Burstein, H. J., Winer, E. P., Dey, T., Sparano, J. A., & Mittendorf, E. A. (2021). Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. Journal of the National Cancer Institute, . https://doi.org/10.1093/jnci/djab095
Kantor, Olga, et al. "Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer." Journal of the National Cancer Institute vol. (2021). doi: https://doi.org/10.1093/jnci/djab095
Kantor O, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Burstein HJ, Winer EP, Dey T, Sparano JA, Mittendorf EA. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Natl Cancer Inst. 2021 May 19; doi: 10.1093/jnci/djab095. Epub 2021 May 19. PMID: 34010423; PMCID: PMC8634483.
Copy Download .nbib Format: NLM
Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Efficace F, Giesinger JM, Cella D, Cottone F, Sparano F, Vignetti M, Aaronson NK.
PMID: 34838268
Value Health. 2021 Dec;24(12):1715-1719. doi: 10.1016/j.jval.2021.06.003. Epub 2021 Aug 09.

OBJECTIVES: Incomplete reporting of key information on patient-reported outcomes (PROs) in randomized controlled trials (RCTs) in oncology has been highlighted repeatedly as a major barrier to the use of study findings in clinical practice. We investigated whether the quality...

Cite
Efficace F, Giesinger JM, Cella D, et al. Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019. Value Health. 2021;24(12):1715-1719doi: 10.1016/j.jval.2021.06.003.
Efficace, F., Giesinger, J. M., Cella, D., Cottone, F., Sparano, F., Vignetti, M., & Aaronson, N. K. (2021). Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(12), 1715-1719. https://doi.org/10.1016/j.jval.2021.06.003
Efficace, Fabio, et al. "Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 24,12 (2021): 1715-1719. doi: https://doi.org/10.1016/j.jval.2021.06.003
Efficace F, Giesinger JM, Cella D, Cottone F, Sparano F, Vignetti M, Aaronson NK. Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019. Value Health. 2021 Dec;24(12):1715-1719. doi: 10.1016/j.jval.2021.06.003. Epub 2021 Aug 09. PMID: 34838268.
Copy Download .nbib Format: NLM
Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer.

NPJ breast cancer

Makower D, Lin J, Xue X, Sparano JA.
PMID: 33649322
NPJ Breast Cancer. 2021 Mar 01;7(1):20. doi: 10.1038/s41523-021-00231-x.

Lymphovascular invasion (LVI) and Black race are associated with poorer prognosis in early breast cancer (EBC). We evaluated the association between LVI and race, and whether LVI adds prognostic benefit to the 21-gene recurrence score (RS) in EBC. Women...

Cite
Makower D, Lin J, Xue X, et al. Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. NPJ Breast Cancer. 2021;7(1):20doi: 10.1038/s41523-021-00231-x.
Makower, D., Lin, J., Xue, X., & Sparano, J. A. (2021). Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. NPJ breast cancer, 7(1), 20. https://doi.org/10.1038/s41523-021-00231-x
Makower, Della, et al. "Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer." NPJ breast cancer vol. 7,1 (2021): 20. doi: https://doi.org/10.1038/s41523-021-00231-x
Makower D, Lin J, Xue X, Sparano JA. Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. NPJ Breast Cancer. 2021 Mar 01;7(1):20. doi: 10.1038/s41523-021-00231-x. PMID: 33649322; PMCID: PMC7921089.
Copy Download .nbib Format: NLM
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy.

Therapeutic advances in medical oncology

Fasano M, Della Corte CM, Viscardi G, Di Liello R, Paragliola F, Sparano F, Iacovino ML, Castrichino A, Doria F, Sica A, Morgillo F, Colella G, Tartaro G, Cappabianca S, Testa D, Motta G, Ciardiello F.
PMID: 33767760
Ther Adv Med Oncol. 2021 Mar 09;13:1758835920949418. doi: 10.1177/1758835920949418. eCollection 2021.

Head and neck cancers (HNC) represent the seventh most frequent cancer worldwide, with squamous cell carcinomas as the most frequent histologic subtype. Standard treatment for early stage diseases is represented by single modality surgery or radiotherapy, whereas in the...

Cite
Fasano M, Della Corte CM, Viscardi G, et al. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Ther Adv Med Oncol. 2021;13:1758835920949418doi: 10.1177/1758835920949418.
Fasano, M., Della Corte, C. M., Viscardi, G., Di Liello, R., Paragliola, F., Sparano, F., Iacovino, M. L., Castrichino, A., Doria, F., Sica, A., Morgillo, F., Colella, G., Tartaro, G., Cappabianca, S., Testa, D., Motta, G., & Ciardiello, F. (2021). Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Therapeutic advances in medical oncology, 131758835920949418. https://doi.org/10.1177/1758835920949418
Fasano, Morena, et al. "Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy." Therapeutic advances in medical oncology vol. 13 (2021): 1758835920949418. doi: https://doi.org/10.1177/1758835920949418
Fasano M, Della Corte CM, Viscardi G, Di Liello R, Paragliola F, Sparano F, Iacovino ML, Castrichino A, Doria F, Sica A, Morgillo F, Colella G, Tartaro G, Cappabianca S, Testa D, Motta G, Ciardiello F. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Ther Adv Med Oncol. 2021 Mar 09;13:1758835920949418. doi: 10.1177/1758835920949418. eCollection 2021. PMID: 33767760; PMCID: PMC7953226.
Copy Download .nbib Format: NLM
Public Engagement and Neurology: An Update.

Brain sciences

Lavorgna L, Brigo F, Esposito S, Abbadessa G, Sparaco M, Lanzillo R, Moccia M, Inglese M, Bonfanti L, Trojsi F, Spina E, Russo A, De Micco P, Clerico M, Tedeschi G, Bonavita S.
PMID: 33800571
Brain Sci. 2021 Mar 28;11(4). doi: 10.3390/brainsci11040429.

BACKGROUND: Public engagement (PE) is defined as the involvement of "specialists who listen, develop their understanding, and interact with non-specialists in non-profit activities of educational, cultural, and social nature to engage the public in science-related matters". The public health...

Cite
Lavorgna L, Brigo F, Esposito S, et al. Public Engagement and Neurology: An Update. Brain Sci. 2021;11(4)doi: 10.3390/brainsci11040429.
Lavorgna, L., Brigo, F., Esposito, S., Abbadessa, G., Sparaco, M., Lanzillo, R., Moccia, M., Inglese, M., Bonfanti, L., Trojsi, F., Spina, E., Russo, A., De Micco, P., Clerico, M., Tedeschi, G., & Bonavita, S. (2021). Public Engagement and Neurology: An Update. Brain sciences, 11(4), . https://doi.org/10.3390/brainsci11040429
Lavorgna, Luigi, et al. "Public Engagement and Neurology: An Update." Brain sciences vol. 11,4 (2021). doi: https://doi.org/10.3390/brainsci11040429
Lavorgna L, Brigo F, Esposito S, Abbadessa G, Sparaco M, Lanzillo R, Moccia M, Inglese M, Bonfanti L, Trojsi F, Spina E, Russo A, De Micco P, Clerico M, Tedeschi G, Bonavita S. Public Engagement and Neurology: An Update. Brain Sci. 2021 Mar 28;11(4). doi: 10.3390/brainsci11040429. PMID: 33800571; PMCID: PMC8065487.
Copy Download .nbib Format: NLM
Correlation of Coping, Mentorship, and Life Events with Burnout in Internal Medicine Residents.

Medical science educator

Spataro BM, Tilstra SA, Rubio DM, McNeil MA.
PMID: 34457912
Med Sci Educ. 2021 Jan 20;31(2):573-579. doi: 10.1007/s40670-021-01215-z. eCollection 2021 Apr.

Physician burnout is a widespread problem. We examined how coping, mentorship, and life events correlated with burnout in Internal Medicine Residents. We performed a cross-sectional study of survey data collected over multiple time points and used Spearman correlation of...

Cite
Spataro BM, Tilstra SA, Rubio DM, et al. Correlation of Coping, Mentorship, and Life Events with Burnout in Internal Medicine Residents. Med Sci Educ. 2021;31(2):573-579doi: 10.1007/s40670-021-01215-z.
Spataro, B. M., Tilstra, S. A., Rubio, D. M., & McNeil, M. A. (2021). Correlation of Coping, Mentorship, and Life Events with Burnout in Internal Medicine Residents. Medical science educator, 31(2), 573-579. https://doi.org/10.1007/s40670-021-01215-z
Spataro, Brielle M, et al. "Correlation of Coping, Mentorship, and Life Events with Burnout in Internal Medicine Residents." Medical science educator vol. 31,2 (2021): 573-579. doi: https://doi.org/10.1007/s40670-021-01215-z
Spataro BM, Tilstra SA, Rubio DM, McNeil MA. Correlation of Coping, Mentorship, and Life Events with Burnout in Internal Medicine Residents. Med Sci Educ. 2021 Jan 20;31(2):573-579. doi: 10.1007/s40670-021-01215-z. eCollection 2021 Apr. PMID: 34457912; PMCID: PMC8368755.
Copy Download .nbib Format: NLM
Social capital or vulnerability: Which has the stronger connection with selected U.S. health outcomes?.

SSM - population health

Borges CM, Pollock JC, Crowley M, Purandare R, Sparano J, Spike K.
PMID: 34141850
SSM Popul Health. 2021 May 05;15:100812. doi: 10.1016/j.ssmph.2021.100812. eCollection 2021 Sep.

We tested associations between social capital or vulnerability and health outcome measures of adult obesity, adult diabetes, and life expectancy at the county level in the United States with data from 2015 to 2018. This ecological cross-sectional study utilized...

Cite
Borges CM, Pollock JC, Crowley M, et al. Social capital or vulnerability: Which has the stronger connection with selected U.S. health outcomes?. SSM Popul Health. 2021;15:100812doi: 10.1016/j.ssmph.2021.100812.
Borges, C. M., Pollock, J. C., Crowley, M., Purandare, R., Sparano, J., & Spike, K. (2021). Social capital or vulnerability: Which has the stronger connection with selected U.S. health outcomes?. SSM - population health, 15100812. https://doi.org/10.1016/j.ssmph.2021.100812
Borges, Carolina M, et al. "Social capital or vulnerability: Which has the stronger connection with selected U.S. health outcomes?." SSM - population health vol. 15 (2021): 100812. doi: https://doi.org/10.1016/j.ssmph.2021.100812
Borges CM, Pollock JC, Crowley M, Purandare R, Sparano J, Spike K. Social capital or vulnerability: Which has the stronger connection with selected U.S. health outcomes?. SSM Popul Health. 2021 May 05;15:100812. doi: 10.1016/j.ssmph.2021.100812. eCollection 2021 Sep. PMID: 34141850; PMCID: PMC8188049.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 102 entries